{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-007147","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.375387+00:00","generated_at":"2026-06-05T23:27:24.643419+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FibroBiologics to present MS data at ACTRIMS; phase 0/1 shows safety, no adverse events","bullets":["Phase 0/1 safety trial of allogeneic HDFs in 5 MS patients: no adverse events, strong CBC/blood chemistry/ECG correlation.","In vivo EAE model: HDFs suppressed Th17, expanded Tregs, stimulated remyelination, outperformed adipose/bone marrow MSCs.","Company designing phase II trial to test various HDF spheroid doses and multiple-dose treatments over 18 months.","Presentation at ACTRIMS Forum 2024 on Feb 29 in West Palm Beach, FL (poster P341)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-007147","json":"https://secwatch.observer/filing/0001493152-24-007147.json","markdown":"https://secwatch.observer/filing/0001493152-24-007147.md","text":"https://secwatch.observer/filing/0001493152-24-007147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000149315224007147/0001493152-24-007147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000149315224007147/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T23:27:24.643419+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}